Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 1, 2008, Pages 32-40

  Von Ruden, Abby E ^a   Adson, David E ^b   Kotlyar, Michael ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Coronary artery disease; Depression; Serotonin uptake inhibitors

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; CORONARY ARTERY DISEASE; DEPRESSION; HEART INFARCTION; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DEPRESSIVE DISORDER, MAJOR; HUMANS; PROGNOSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 39049120250     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407308467     Document Type: Review

References (56)

1. Lesperance F., Frasure-Smith N., Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med. 1996 ; 58: 99-110.
2. Jiang W., Davidson JR Antidepressant therapy in patients with ischemic heart disease. Am Heart J. 2005 ; 150: 871-881.
3. Anda R., Williamson D., Jones D., et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993 ; 4: 285-294.
4. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996 ; 94: 3123-3129.
5. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004 ; 66: 305-315.
6. van Melle JP, de Jonge P., Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004 ; 66: 814-822.
7. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995 ; 14: 88-90.
8. Gehi A., Haas D., Pipkin S., Whooley MA Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005 ; 165: 2508-2513.
9. Ades PA, Waldmann ML, McCann WJ, Weaver SO Predictors of cardiac rehabilitation participation in older coronary patients. Arch Intern Med. 1992 ; 152: 1033-1035.
10. Glazer KM, Emery CF, Frid DJ, Banyasz RE Psychological predictors of adherence and outcomes among patients in cardiac rehabilitation. J Cardiopulm Rehabil. 2002 ; 22: 40-46.
11. Bonnet F., Irving K., Terra JL, et al. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis. 2005 ; 178: 339-344.
12. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA. 1990 ; 264: 1546-1549.
13. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 ; 24: 1069-1078.
14. Zorrilla EP, Luborsky L., McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001 ; 15: 199-226.
15. Walsh MT, Dinan TG, Condren RM, Ryan M., Kenny D. Depression is associated with an increase in the expression of the platelet adhesion receptor glycoprotein Ib. Life Sci. 2002 ; 70: 3155-3165.
16. Laghrissi-Thode F., Wagner WR, Pollock BG, Johnson PC, Finkel MS Elevated platelet factor 4 and betathromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997 ; 42: 290-295.
17. Nahshoni E., Aravot D., Aizenberg D., et al. Heart rate variability in patients with major depression. Psychosomatics. 2004 ; 45: 129-134.
18. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001 ; 104: 2024-2028.
19. Plotsky PM, Owens MJ, Nemeroff CB Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am. 1998 ; 21: 293-307.
20. Gillespie CF, Nemeroff CB Hypercortisolemia and depression. Psychosom Med. 2005 ; 67 (suppl 1). S26 - S28.
21. Sheffield D., Krittayaphong R., Cascio WE, et al. Heart rate variability at rest and during mental stress in patients with coronary artery disease: differences in patients with high and low depression scores. Int J Behav Med. 1998 ; 5: 31-47.
22. Light KC, Kothandapani RV, Allen MT Enhanced cardiovascular and catecholamine responses in women with depressive symptoms. Int J Psychophysiol. 1998 ; 28: 157-166.
23. Roose SP Treatment of depression in patients with heart disease. Biol Psychiatry. 2003 ; 54: 262-268.
24. Alvarez W. Jr, Pickworth KK Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy. 2003 ; 23: 754-771.
25. Lesperance F., Frasure-Smith N., Koszycki D., et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007 ; 297: 367-379.
26. Swenson JR, Doucette S., Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006 ; 51: 923-929.
27. Kennedy J., Coyne J., Sclar D. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther. 2004 ; 26: 607-614.
28. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002 ; 288: 701-709.
29. Berkman LF, Blumenthal J., Burg M., et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003 ; 289: 3106-3116.
30. Taylor CB, Youngblood ME, Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005 ; 62: 792-798.
31. Sauer WH, Berlin JA, Kimmel SE Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001 ; 104: 1894-1898.
32. Sauer WH, Berlin JA, Kimmel SE Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003 ; 108: 32-36.
33. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001 ; 52: 179-184.
34. Schlienger RG, Fischer LM, Jick H., Meier CR Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004 ; 27: 1157-1165.
35. Tata LJ, West J., Smith C., et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005 ; 91: 465-471.
36. Walley T., Mantgani A. The UK general practice research database. Lancet. 1997 ; 350: 1097-1099.
37. Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sorensen HT Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med. 2004 ; 117: 732-737.
38. Hippisley-Cox J., Pringle M., Hammersley V., et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ. 2001 ; 323: 666-669.
39. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ. 1996 ; 313: 860-861.
40. Cohen HW, Gibson G., Alderman MH Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000 ; 108: 2-8.
41. Xiong GL, Jiang W., Clare R., et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol. 2006 ; 98: 42-47.
42. Tiihonen J., Lonnqvist J., Wahlbeck K., et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006 ; 63: 1358-1367.
43. McFarlane A., Kamath MV, Fallen EL, et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001 ; 142: 617-623.
44. Balogh S., Fitzpatrick DF, Hendricks SE, Paige SR Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull. 1993 ; 29: 201-206.
45. Nikisch G., Mathe AA, Czernik A., et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology. 2005 ; 181: 751-760.
46. Serebruany VL Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006 ; 119: 113-116.
47. Pollock BG, Laghrissi-Thode F., Wagner WR Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000 ; 20: 137-140.
48. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry. 2000 ; 157: 1006-1008.
49. Atar D., Malinin A., Takserman A., et al. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol. 2006 ; 26: 172-177.
50. Serebruany VL, Gurbel PA, O'Connor CM Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001 ; 43: 453-462.
51. Shores MM, Pascualy M., Lewis NL, Flatness D., Veith RC Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology. 2001 ; 26: 433-439.
52. Golding M., Kotlyar M., Carson SW, et al. Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. Psychopharmacology. 2005 ; 182: 321-326.
53. Golding M., Kotlyar M., Garbutt JC, et al. Paroxetine modulates psychological and sympathetic responses during public speaking. J Clin Psychopharmacol. 2002 ; 22: 98-99.
54. Joynt KE, O'Connor CM Lessons from SADHART, ENRICHD, and other trials. Psychosom Med. 2005 ; 67 (suppl 1). S63 - S66.
55. Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med. 2006 ; 68: 645-650.
56. Whooley MA Depression and cardiovascular disease: healing the broken-hearted. JAMA. 2006 ; 295: 2874-2881.